Tumors develop strategies to interfere with effective anti‐tumor immune responses, ranging from the induction or generation of suppressive immune populations to the deletion or functional impairment of tumor‐reactive T cells.[33, 34] Our study identifies a novel protumorigenic FasL+PD‐L2+ neutrophil subset in GC and reveals that FasL+PD‐L2+ neutrophil subset contributes to tumor progression, which is consistent with our observations that advanced tumor stages are associated with significant increase of FasL+PD‐L2+ neutrophils in GC tumors. This evidence concerns the gene PDCD1LG2 and neoplasm.